Stealth BioTherapeutics to Present at Mitochondria-Targeted Drug Development Summit
Retrieved on:
Tuesday, February 22, 2022
Eye, Therapy, Lists of diseases, Risk, Stealth, Neuromuscular Disorders, IgG4-related ophthalmic disease, Glaucoma, Barth syndrome, Annual report, COVID-19, Frontotemporal dementia, Clinical trial, Degenerative disease, Duchenne, GA, Pathology, Heart, Mitochondrial myopathy, Cardiomyopathy, Amyotrophic lateral sclerosis, Safety, Hope, AMD, DNA, Brain, Private Securities Litigation Reform Act, Diabetic retinopathy, FDA, Nasdaq, EMA, Forward-looking statement, Patient, Marketing, Patent, U.S. Securities and Exchange Commission, CEO, Fuchs' dystrophy, Duchenne muscular dystrophy, Pharmaceutical industry, Mitochondrion
BOSTON, Feb. 22, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at the virtual Mitochondria-Targeted Drug Development Summit on Thursday, February 24, 2022 at 9:00 a.m.
Key Points:
- BOSTON, Feb. 22, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at the virtual Mitochondria-Targeted Drug Development Summit on Thursday, February 24, 2022 at 9:00 a.m.
- For more information about the event, please visit: https://mitochondria-targets.com/
We are a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction. - Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function.
- Except as required by law,Stealth BioTherapeuticsdoes not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances.